Oncternal therapeutics, inc. (ONCT)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Grant revenue

2,425

2,521

-

-

-

-

-

-

-

-

14,730

Product sales, net

-

-

-

-

-

-

-

-

-

-

3,289

Collaboration revenue

-

-

-

-

-

-

-

-

8,066

56,786

11,441

Operating expenses:
Cost of product sales

-

-

-

-

-

-

-

-

-

-

1,290

Research and development

10,159

8,287

21,467

17,228

13,607

20,870

32,318

38,887

31,938

28,495

32,344

In-process research and development

18,088

-

-

-

-

-

-

-

-

-

-

General and administrative

7,286

1,820

9,188

8,705

8,234

9,478

11,281

10,845

12,027

13,194

-

Total operating expenses

35,533

10,107

30,655

25,933

21,841

30,348

43,599

49,732

43,965

41,689

-

General and administrative expenses

-

-

-

-

-

-

-

-

-

-

27,778

Total costs and expenses

-

-

-

-

-

-

-

-

-

-

61,412

Loss from operations

-33,108

-7,586

-30,655

-25,933

-21,841

-30,348

-43,599

-49,732

-35,899

15,097

-46,682

Other income:
Change in fair value of warrant liability

1,268

-713

-

-8,163

-3,081

8,804

-

-

-

-

-

Other income

-

216

-

-

-

-

-

-

-

-

-

Interest expense

-

1

-

-

-

-

-

-

-

-

-

Interest income

188

79

-

-

-

-

-

-

-

-

-

Total other income

-1,080

1,007

216

46

57

-259

1,488

-19

398

1,363

188

Income from discontinued operations before income taxes

-

-

-

-

-

-

-

22,676

2,207

-1,166

-

Income tax expense

-

-

-

-

-

-

-

8,821

886

-

-

Net income from discontinued operations

-

-

-

-

-

-

-

13,855

1,321

-1,166

-

Net loss

-34,188

-6,579

-30,439

-17,724

-18,703

-39,411

-42,111

-27,075

-33,294

15,294

-46,256

Loss from operations before income taxes

-

-

-

-

-

-

-

-49,751

-35,501

16,460

-46,494

Income tax benefit

-

-

-

-

-

-

-

-8,821

-886

-

-238

Net loss from continuing operations

-

-

-

-

-

-

-

-40,930

-34,615

16,460

-

Basic (in dollars per share)

-

-

-

-

-1.33

-4.82

-0.67

-

-

-

-

Diluted (in dollars per share)

-

-

-

-

-1.47

-4.82

-0.67

-

-

-

-

Net loss from continuing operations (in dollars per share)

-

-

-

-

-

-

-

-0.65

-0.60

0.42

-

Net income from discontinued operations (in dollars per share)

-

-

-

-

-

-

-

0.22

0.02

-0.03

-

Net loss per share, basic and diluted

-3.31

-1.83

-1.75

-1.22

-

-

-

-0.43

-0.58

0.39

-1.27

Basic (in shares)

-

-

-

-

14,036

8,180

63,057

-

-

-

-

Diluted (in shares)

-

-

-

-

14,777

8,180

63,057

-

-

-

-

Weighted-average shares outstanding, basic and diluted

10

3

17,441

14,559

-

-

-

62,809

57,359

38,874

-

Basic and diluted

-

-

-

-

-

-

-

-

-

-

36,415